Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd - 44756 - abdominal hernia surgical mesh, composite-polymer - symbotextm composite mesh is made of a three-dimensional (3d) monofilament polyester textile, which is covered with an absorbable, continuous and hydrophilic film on one of its sides. the non-absorbable three-dimensional polyester provides long term reinforcement of soft tissues. on the opposite side, the absorbable hydrophilic film minimizes tissue attachment to the mesh in case of direct contact with the viscera. the collagen film is essentially degraded in less than 1 month. symbotex? composite mesh is intended for the reinforcement of abdominal wall soft tissue where a weakness exists, in procedures involving primary abdominal wall and incisional hernia surgeries. the non-absorbable three-dimensional polyester mesh provides long term reinforcement of soft tissues. on the opposite side, the absorbable hydrophilic film minimizes tissue attachment to the mesh in case of direct contact with the viscera.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd - 44756 - abdominal hernia surgical mesh, composite-polymer - parietex composite ventral patch is a dual facing mesh composed of a non-absorbable three-dimensional (3d) monofilament polyester textile for abdominal wall reinforcement (ventral defect) covered by a bioabsorbable hydrophilic collagen film to minimize visceral attachment. a fixation system composed of four flaps made out of monofilament polyester textile and two removable handles completes the device. this system facilitates placement and fixation of the mesh. intended for the reinforcement of abdominal wall soft tissue where a weakness exists, in procedures involving primary ventral hernia repair.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - ceftazidime pentahydrate, quantity: 1.16 g - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime-aft is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: ? severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, eg, infected burns. ? respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. ? severe ear, nose and throat infections: for example, otitis media, mastoiditis. ? urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. ? skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. ? gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. ? bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - ceftazidime pentahydrate, quantity: 2.33 g - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime-aft is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: ? severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, eg, infected burns. ? respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. ? severe ear, nose and throat infections: for example, otitis media, mastoiditis. ? urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. ? skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. ? gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. ? bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

cordis australia pty ltd - 46777 - abdominal aortic aneurysm stent - the prostheses is loaded onto a delivery system component. the delivery system facilitates precise placement of the prosthesis into the vasculature via fluoroscopy. following deployment of the prosthesis, its exposure to blood at body temperature causes the stents to self-expand to their pre-set diameters. intended for the endovascular treatment of patients with infrarenal abdominal aortic aneurysms with the following characteristics: femoral access vessels should be adequate to fir the selected delivery system,proximal neck length greater or equal to 10mm, aortic neck diameters greater or equal to 17mm and less than or equal to 31mm, aortic neck suitable for suprarenal fization, infrarenal and suprarenal neck angulation less than or equal to 60 degrees, illiac fixation length geeater than or equal to 15mm, illiac diameters greater or equal to 7 mm and less than or equal to 22mm, minimum overall aaa treatment length (proximal landing location to distal landing location) greater than or equal to 128mm, morphology suitable for aneurysm repair.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - ceftazidime pentahydrate, quantity: 2329.6 mg (equivalent: ceftazidime, qty 2 g) - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: - sever infections in general: for expample septicaemia (including neonatal sepsis), bacteraemia, patients in intensive care units with specific problems, e.g infected burns. - respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis, bronchitis. - sever ear, nose and throat infections: for example, otitis media, mastoiditis. - urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), infections associated with bladder and renal stones. - skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. - gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. - bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - ceftazidime pentahydrate, quantity: 1164.8 mg (equivalent: ceftazidime, qty 1 g) - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: - sever infections in general: for expample septicaemia (including neonatal sepsis), bacteraemia, patients in intensive care units with specific problems, e.g infected burns. - respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis, bronchitis. - sever ear, nose and throat infections: for example, otitis media, mastoiditis. - urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), infections associated with bladder and renal stones. - skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. - gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. - bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

alliance surgical pty ltd - 44756 - abdominal hernia surgical mesh, composite-polymer - the dome mesh and onlay patch are packaged together as a plug and patch technique. the dome mesh is a semiresorbable reinforcement parietal implant, constructed of 10% non-resorbable light polypropylene and 90% resorbable plla in which the plla component takes 6 months to resorb and the polypropylene is left to strengthen the fascia; whilst the onlay patch which is the anterior implant is 75% plla and 25% polypropylene. the device is intended for abdominal reinforcement including inguinal and femoral hernias.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

koala medical pty ltd - 14155 - trocar, abdominal - a surgical instrument which is supplied sterile and features a sharp pyramidal or conical point used to puncture the abdominal wall. it can be assembled and used together with a compatible sleeve filling its lumen, thereby allowing the introduction of this assembly. following puncture, the trocar is withdrawn providing a working channel to the cavity. the tropian trocar may have a filter which provides filtration and/or removal of particulates and odours generated during surgical procedures in which there maybe tissue ablation.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

c r kennedy & co pty ltd - 13375 - retractor, abdominal - a surgical instrument intended for separating the edges of an abdominal incision to expose or access organs or tissues to permit examination or intervention.